Metabolic Control of Aging and Disease - the MetAGE Deep Phenotyping Cohort
NCT ID: NCT06511297
Last Updated: 2026-02-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
650 participants
OBSERVATIONAL
2025-05-05
2036-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main question is to gain insights into the interaction of obesity related metabolic alteration and aging, and the relevance of loss of metabolic control in the development of age-related diseases in order to build a foundation for targeted drug- and lifestyle interventions in future studies.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Metabolic Phenotyping in Humans
NCT01298375
Metabolomics of Aging: Sub-study of the Healthy Elderly Active Longevity (HEAL) Study
NCT01209884
Investigating the Possible Link Between Habitual Diet, Physical Activity, Sleeping Patterns, Obesity Status and Age With Gut Bacterial Composition, Gut Barrier Function, Metabolic Endotoxemia, Systemic Inflammation and Glycaemic Control.
NCT03864107
Assessment of Progranulin and FAM19A5 Protein Blood Levels in Metabolic Syndrome
NCT04451616
Metabolomics Predictors for Metabolic Disease Remission After Metabolic Syndrome Surgery.
NCT06645730
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The Pro-MetAGE prospective cohort as part of the clinical program of the MetAGE Cluster of Excellence (Austrian Science Fund # 10.55776/COE14) will focus on understanding the metabolic dysregulation associated with aging in a metabolic at-risk population. Metabolic control, which encompasses various aspects and is influenced by numerous aging indicators, might be the primary driver of age-related diseases. For instance, contemporary markers of biological age, such as epigenetic clocks based on DNA methylation and cellular senescence markers, correlate more closely with metabolic processes like nutrient sensing and mitochondrial function rather than genome stability or telomere length.
Aging entails a gradual deterioration of several fundamental metabolic processes, including lipostasis (fat metabolism), proteostasis (protein homeostasis), polyamine metabolism, and mitochondrial function. These intracellular changes are compounded by alterations in intercellular and interorgan communication, affecting brain-organ interactions and immune function. The decline in these crucial processes can disrupt the regulatory mechanisms of metabolic control in a manner influenced by sex and gender. Consequently, the loss of metabolic control may exacerbate other aging processes, setting off a detrimental cycle of accelerated aging.
Disruption in metabolic regulation caused by calorie-rich diets, disturbed circadian rhythms, or sedentary lifestyle can lead to a diverse set of health issues known collectively as metabolic syndrome. These medical conditions, including obesity, high blood pressure, elevated lipid levels, insulin resistance, and high blood sugar, contribute to the development of prevalent age-related diseases such as cardiovascular disease, type 2 diabetes, retinal degeneration and metabolic dysfunction-associated steatotic liver disease, formerly known as nonalcoholic fatty liver disease, affecting millions of older individuals globally. Additionally, there exists a significant link between metabolic imbalance and dysfunction in the immune system, resulting in heightened susceptibility to infections, diminished response to vaccinations, and various neuropsychiatric disorders, especially depression. Hence, understanding the mechanisms underlying metabolic dysregulation holds immense importance in devising preventive measures against some of the most debilitating age-related ailments.
The proposed research project aims to prospectively identify and validate aging biomarkers in relation to age- and sex-related cardiometabolic changes in young and old individuals, who are lean or obese/overweight (i.e. a metabolic at-risk population) with regard to lipostasis, proteostasis, polyamine metabolism, mitochondrial function, inflammation and cellular senescence. The goal is to gain insights into the interaction of obesity related metabolic alteration and aging, and the relevance of loss of metabolic control in the development of age-related diseases in order to build a foundation for targeted drug- and lifestyle interventions in future studies.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Lean, young adults
comprehensive metabolic phenotyping
The investigators will employ state of the art techniques to metabolically phenotype the study groups using brain, cardiac and whole body magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), wearables, optical coherence tomography longitudinally. In addition, a battery of patient reported outcome measures will be used to explore psychosocial aspects of aging.
Overweight, young adults
comprehensive metabolic phenotyping
The investigators will employ state of the art techniques to metabolically phenotype the study groups using brain, cardiac and whole body magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), wearables, optical coherence tomography longitudinally. In addition, a battery of patient reported outcome measures will be used to explore psychosocial aspects of aging.
Lean, older adults
comprehensive metabolic phenotyping
The investigators will employ state of the art techniques to metabolically phenotype the study groups using brain, cardiac and whole body magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), wearables, optical coherence tomography longitudinally. In addition, a battery of patient reported outcome measures will be used to explore psychosocial aspects of aging.
Overweight, older adults
comprehensive metabolic phenotyping
The investigators will employ state of the art techniques to metabolically phenotype the study groups using brain, cardiac and whole body magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), wearables, optical coherence tomography longitudinally. In addition, a battery of patient reported outcome measures will be used to explore psychosocial aspects of aging.
Nonagenerians Age ≥ 90
Note: Nonagenarian Group will only be phenotyped once
comprehensive metabolic phenotyping
The investigators will employ state of the art techniques to metabolically phenotype the study groups using brain, cardiac and whole body magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), wearables, optical coherence tomography longitudinally. In addition, a battery of patient reported outcome measures will be used to explore psychosocial aspects of aging.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
comprehensive metabolic phenotyping
The investigators will employ state of the art techniques to metabolically phenotype the study groups using brain, cardiac and whole body magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), wearables, optical coherence tomography longitudinally. In addition, a battery of patient reported outcome measures will be used to explore psychosocial aspects of aging.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 18 - 35 years
* Body mass index (BMI) ≥ 18.5 and ≤ 24.9 kg/m2 (≥ 12 months)
Group 2 - Overweight, young adults (n = 150)
* Age 18 - 35 years
* BMI ≥ 28kg/m2 (≥ 12 months)
Group 3 - Lean, older adults (n = 150)
* Age ≥ 60 years
* BMI ≥ 18.5 and ≤ 24.9 kg/m2 (≥ 3 years)
Group 4 - Overweight, older adults (n = 150)
* Age ≥ 60 years
* BMI ≥ 28 kg/m2 (≥ 3 years)
* Subgroup A (n=75): with pre-existent cardiovascular disease defined as: history of myocardial infarction or evidence of coronary artery disease irrespective of revascularization status or history of ischemic or hemorrhagic stroke or presence of peripheral artery disease or heart failure with preserved ejection fraction (NYHA Class I-II).
* Subgroup B (n=75): without pre-existent cardiovascular disease
Group 5 - Nonagenerians Age ≥ 90 (n = 50)
* Age ≥ 90 years
* BMI ≥ 18.5 kg/m2 (≥ 3 years)
Exclusion Criteria
* Highly physical active (i.e. \> 5 times sporting activity / week with moderate to high intensity \[heart rate 140 - 200bpm\])
* Special diets (i.e. ketogenic diet and time-restricted eating)
* Clinically significant metabolic or endocrine disorders
* Claustrophobia
* drug abuse, alcohol \> 15 drinks/week
* Heart failure, cardiovascular disease, immunosuppressive therapies, chronic inflammatory diseases and active oncologic conditions
* Metal implants that prohibit 3T MRI
* Pregnancy or breastfeeding
Group 2 - Overweight, young adults (n = 150)
* Highly physical active (i.e. \> 5 times sporting activity / week with moderate to high intensity \[heart rate 140 - 200bpm\])
* Special diets (i.e. ketogenic diet and time-restricted eating)
* Active anti-obesity treatment (e.g. glucagon-like peptide 1 (GLP-1) analogues, polyagonists, naltrexone and bupropion)
* Clinically significant metabolic or endocrine disorders
* Claustrophobia
* drug abuse, alcohol \> 15 drinks/week
* Heart failure, cardiovascular disease, immunosuppressive therapies, chronic inflammatory diseases and active oncologic conditions
* Metal implants that prohibit 3T MRI
* Pregnancy or breastfeeding
Group 3 - Lean, older adults (n = 150)
* Highly physical active (i.e. \> 5 times sporting activity / week with moderate to high intensity \[heart rate 140 - 200bpm\])
* Special diets (i.e. ketogenic diet and time-restricted eating)
* Diabetes, overt hypo/hyperthyroidism
* Claustrophobia
* drug abuse, alcohol \> 15 drinks/week
* Metal implants that prohibit 3T MRI
* Known severe cardiovascular diseases (i.e. PAD IIa or higher, advanced heart failure = left ventricular ejection fraction (LVEF) \< 35% or NYHA Class III-IV)
* No previous heart failure, cardiovascular disease, immunosuppressive therapies, chronic inflammatory diseases and active oncologic conditions up until the age of 35 years.
* Life-threatening conditions with a life expectancy of less than 1 year or any other condition that would jeopardize proband safety/adherence while participating in this trial.
Group 4 - Overweight, older adults (n = 150)
* Special diets (i.e. ketogenic diet and time-restricted eating)
* Diabetes, overt hypo/hyperthyroidism
* Active anti-obesity treatment (e.g. GLP-1 analogues, polyagonists, naltrexone and bupropion)
* Claustrophobia
* drug abuse, alcohol \> 15 drinks/week
* Metal implants that prohibit 3T MRI
* No previous heart failure, cardiovascular disease, immunosuppressive therapies, chronic inflammatory diseases and active oncologic conditions up until the age of 35 years.
* Life-threatening conditions with a life expectancy of less than 1 year or any other condition that would jeopardize proband safety/adherence while participating in this trial.
Group 5 - "healthy" Nonagenerians Age ≥ 90 (n = 50)
* Claustrophobia
* Clinically significant cognitive impairment compromising study adherence
* Metal implants that prohibit 3T MRI
* Life-threatening conditions with a life expectancy of less than 1 year or any other condition that would jeopardize proband safety/adherence while participating in this trial.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medical University of Graz
OTHER
University of Graz
OTHER
Thomas Scherer
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Thomas Scherer
Assoc. Prof. Dr. med.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medical University of Graz
Graz, Styria, Austria
Medical University of Vienna
Vienna, Vienna, Austria
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1632/2024
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.